News, markets, and regulation in Europe, Asia, and South America.
March 1, 2012
By:
Reflector
After his predecessor and countryman left the EMA in disgrace, Guido Rasi jumps in as executive director—with great challenges ahead.
|
February 1, 2012
By:
Reflector
The EU's Innovative Medicines Initiative is helping to invigorate new drug development, but there are still many hurdles to tackle before its promise is realized.
|
January 1, 2012
By:
Reflector
A turbulent year is ahead for European pharma, while EFPIA's Director General begins to rethink its approach to new science.
|
December 1, 2011
By:
Reflector
The effect on pharma of the EU's Transparency Directive has been overly constraining, but will the mooted revisions offer any room to maneuver?
|
November 1, 2011
By:
Julian Upton
The EC's latest proposals have thrown water on Europe's firey Direct-to-Consumer advertising debate. But is it enough to keep the flames at bay?
|
|
November 1, 2011
Will the structure and ambiguity of Germany's new medicines pricing system bring a halt to new drug launches in Europe's largest market?
|
|
October 1, 2011
Success in the emerging markets depends significantly on navigating the myths and mental traps.
|
September 1, 2011
By:
William Looney
Pharm Exec talks to Dr. Mel Spigelman, President and CEO of the TB Alliance, about the organization's tuberculosis priorities.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
